By regulating cyclin-cyclin-dependent kinase (CDK) complex activity, individual CDK inhibitors (CDKIs) are potential tumor suppressors. One of the CDKIs, p27/Kip1, binds to a variety of CDK-cyclin complexes. A link between loss of p27/Kip1 function and development of pituitary tumors was suggested by the formation of pituitary tumors in almost all mice with germline deletion of the p27/Kip1 gene. However, genetic aberrations in the p27/Kip1 locus have not been analyzed in human pituitary tumors. We investigated eighteen non-functioning and GH-secreting pituitary tumor samples for p27/Kip1 mutations by single-strand conformational polymorphism (SSCP) following PCR. We found five abnormally migrating samples on the PCR-SSCP analysis. The sequence of these samples revealed a polymorphism of codon 109 (Val-->Gly), which has been previously described. No other structural changes of p27/Kip1 were found in these pituitary tumors within the coding region. In addition, no difference in p27/Kip1 protein levels in pituitary tumor tissues compared with normal pituitary tissues was demonstrated by immunostaining. These data suggest that both p27/Kip1 mutations and decreases in p27/Kip1 protein levels are infrequent in the development of pituitary tumors.

This article has been cited by other articles:

				M. Grant, H. Alturaihi, P. Jaquet, B. Collier, and U. Kumar Cell Growth Inhibition and Functioning of Human Somatostatin Receptor Type 2 Are Modulated by Receptor Heterodimerization Mol. Endocrinol., October 1, 2008; 22(10): 2278 - 2292. [Abstract] [Full Text] [PDF]

				M. Georgitsi, A. Raitila, A. Karhu, R. B. van der Luijt, C. M. Aalfs, T. Sane, O. Vierimaa, M. J. Makinen, K. Tuppurainen, R. Paschke, et al. Germline CDKN1B/p27Kip1 Mutation in Multiple Endocrine Neoplasia J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3321 - 3325. [Abstract] [Full Text] [PDF]

				E. Hubina, A. M Nanzer, M. R Hanson, E. Ciccarelli, M. Losa, D. Gaia, M. Papotti, M. R. Terreni, S. Khalaf, S. Jordan, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur. J. Endocrinol., August 1, 2006; 155(2): 371 - 379. [Abstract] [Full Text] [PDF]

				M. Korbonits, H. S. Chahal, G. Kaltsas, S. Jordan, Y. Urmanova, Z. Khalimova, P. E. Harris, W. E. Farrell, F.-X. Claret, and A. B. Grossman Expression of Phosphorylated p27Kip1 Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2635 - 2643. [Abstract] [Full Text] [PDF]

				R. S. Muraoka, A. E.G. Lenferink, J. Simpson, D. M. Brantley, L. R. Roebuck, F. M. Yakes, and C. L. Arteaga Cyclin-dependent Kinase Inhibitor p27Kip1 Is Required for Mouse Mammary Gland Morphogenesis and Function J. Cell Biol., May 21, 2001; 153(5): 917 - 932. [Abstract] [Full Text] [PDF]

				K. Lidhar, M. Korbonits, S. Jordan, Z. Khalimova, G. Kaltsas, X. Lu, R. N. Clayton, P. J. Jenkins, J. P. Monson, G. M. Besser, et al. Low Expression of the Cell Cycle Inhibitor p27Kip1 in Normal Corticotroph Cells, Corticotroph Tumors, and Malignant Pituitary Tumors J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3823 - 3830. [Abstract] [Full Text] [PDF]

				P. Henriet, Z.-D. Zhong, P. C. Brooks, K. I. Weinberg, and Y. A. DeClerck Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1 PNAS, August 29, 2000; 97(18): 10026 - 10031. [Abstract] [Full Text] [PDF]

				Y. Jiang, R. C. H. Zhao, and C. M. Verfaillie Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity PNAS, September 12, 2000; 97(19): 10538 - 10543. [Abstract] [Full Text] [PDF]